Arcturus Therapeutics Holdings Inc. — Form 8-K
Filed July 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
On June 26, 2026, Arcturus Therapeutics entered into a strategic collaboration with Thermo Fisher Scientific comprising (1) a Master Services Agreement where Thermo Fisher will contribute up to $40 million in clinical manufacturing services and Arcturus will engage PPD for up to $40 million in CRO services, and (2) a Project Agreement for technical transfer, clinical manufacturing, and related services. Upon regulatory approval of ARCT-032 for cystic fibrosis, Thermo Fisher receives exclusive commercial manufacturing rights under a separate agreement to be negotiated. The MSA has a 5-year initial term with automatic one-year renewals.
Why this rating
De-risks development execution and manufacturing scale-up for lead CF program. $40M each in committed services material to ~$323M market cap. Thermo Fisher's CDMO backing strengthens Phase 3 pathway and commercial readiness.
Extracted items
- 1.01 material agreement
- 7.01 Reg FD disclosure
- 9.01 exhibits
View original filing on SEC.gov ↗
See more from July 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.